Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.77 |
| ▸ | RXRA | P19793 | 2/20 | 0.75 |
| ▸ | RXRB | P28702 | 2/20 | 0.75 |
| ▸ | RXRG | P48443 | 2/20 | 0.75 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.59 |
| ▸ | BAD | Q92934 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 2/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.54 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.54 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.54 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5313295 | 0.98 | SRD5A2 (0.74) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| SCHEMBL78879 | 0.93 | SRD5A2 (0.87) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| SCHEMBL1330891 | 0.93 | SRD5A2 (0.87) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| SCHEMBL6762584 | 0.91 | SRD5A2 (0.83) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| Hydrochloric Acid SCHEMBL8432890 | 0.91 | SRD5A2 (0.83) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| SCHEMBL23521062 | 0.91 | SRD5A2 (0.83) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| Water SCHEMBL28138640 | 0.91 | SRD5A2 (0.83) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| SCHEMBL29208531 | 0.91 | SRD5A2 (0.83) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| SCHEMBL1042428 | 0.91 | SRD5A2 (0.83) | SRD5A2RXRARXRBRXRGCYP2C8 | |
| Ethylene SCHEMBL715322 | 0.89 | SRD5A2 (0.80) | SRD5A2RXRARXRBRXRGCYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| US-7368462-B1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | claimed |
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | claimed |
| WO-2007044574-A2 | PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION THEREOF, AND METHODS OF TREATMENT | TRANSTECH PHARMA, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-20070082952-A1 | Pharmaceutical compositions, methods of preparation thereof, and methods of treatment | TRANSTECH PHARMA, INC. | 2007-04-12 | — | — | US | claimed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | claimed |
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | claimed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | claimed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | claimed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | claimed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2025-06-05 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
| EP-0341514-A2 | Process for the preparation of asymmetrical biaryle compounds | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | SRD5A2 2082/4885RXRA 3714/4885RXRB 2415/4885 |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | SRD5A2 671/4885RXRA 1395/4885RXRB 1565/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | SRD5A2 2235/4885RXRA 4456/4885RXRB 4252/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | SRD5A2 447/4885RXRA 378/4885RXRB 394/4885 |
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SRD5A2 303/4885RXRA 53/4885RXRB 66/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | SRD5A2 3206/4885RXRA 139/4885RXRB 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.